The contract aligns with CIGNA’s longstanding dedication as a champion for customer choice and high-quality, comprehensive look after its customers. Cancers affects a growing population, and we focus on empowering cancer individuals and their families with increased access and choice to affordable, quality health care, said Sue Podbielski, President, CIGNA HealthCare Midwest Marketplaces. The addition of CTCA to our national network gives CIGNA customers access to a style of care that targets the average person needs of cancer sufferers and improving their quality of life.Can-Fite recently participated within an Israeli existence sciences delegation to Japan with Israel's Office of the Chief Scientist and signed nondisclosure Agreements with selected Japanese companies thinking about licensing CF101 and CF102. The Firm's agreement with Korea-based Kwang Dong remains in place. Definitive Agreement to Acquire Improved Vision Program by Can-Fite Subsidiary OphthaliX Through the second quarter of 2015, OphthaliX, Can-Fite's subsidiary, which develops ophthalmic indications of CF101, signed a definitive contract to obtain Israel-based Improved Vision Systems, LTD.